<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Delandistrogene moxeparvovec: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Delandistrogene moxeparvovec: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Delandistrogene moxeparvovec: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="141855" href="/d/html/141855.html" rel="external">see "Delandistrogene moxeparvovec: Drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58441050"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Elevidys</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F58339549"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Gene Therapy, Adeno-Associated Virus</span></li></ul></div>
<div class="block dop drugH1Div" id="F58359689"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cc06b31-bbc9-4530-9118-12d395c83705">Duchenne muscular dystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Duchenne muscular dystrophy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Postpone therapy if any signs and/or symptoms of infection are present due to increased risk of systemic immune response; do not initiate therapy until infection is resolved. One day <b>or</b> 1 week (depending on baseline corticosteroid regimen) prior to infusion, begin oral corticosteroid regimen (see “Concomitant therapy”). Patient should be brought up to date on all age-appropriate vaccines based on current immunization schedules; vaccine should be administered ≥4 weeks prior to initiation of corticosteroid regimen. Evaluate baseline liver function, platelets, troponin-I, and anti-AAVrh74 total binding antibody titers; do not administer if anti-AAVrh74 total binding antibody titers are ≥1:400.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;6 years: IV infusion: 1.33 x 10<sup>14</sup> vector genomes/kg as a single dose.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Dose Volume Based on Weight Range</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">Weight range</p></th>
<th align="left">
<p style="text-indent:0em;">Dose volume</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">10 to 10.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">100 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">10.5 to 11.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">110 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">11.5 to 12.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">120 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">12.5 to 13.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">130 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">13.5 to 14.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">140 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">14.5 to 15.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">150 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">15.5 to 16.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">160 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">16.5 to 17.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">170 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">17.5 to 18.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">180 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">18.5 to 19.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">190 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">19.5 to 20.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">200 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">20.5 to 21.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">210 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">21.5 to 22.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">220 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">22.5 to 23.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">230 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">23.5 to 24.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">240 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">24.5 to 25.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">250 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">25.5 to 26.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">260 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">26.5 to 27.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">270 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">27.5 to 28.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">280 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">28.5 to 29.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">290 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">29.5 to 30.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">300 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30.5 to 31.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">310 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">31.5 to 32.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">320 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">32.5 to 33.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">330 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">33.5 to 34.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">340 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">34.5 to 35.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">350 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">35.5 to 36.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">360 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">36.5 to 37.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">370 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">37.5 to 38.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">380 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">38.5 to 39.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">390 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">39.5 to 40.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">400 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">40.5 to 41.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">410 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">41.5 to 42.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">420 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">42.5 to 43.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">430 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">43.5 to 44.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">440 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">44.5 to 45.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">450 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">45.5 to 46.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">460 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">46.5 to 47.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">470 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">47.5 to 48.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">480 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">48.5 to 49.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">490 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">49.5 to 50.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">500 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">50.5 to 51.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">510 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">51.5 to 52.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">520 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">52.5 to 53.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">530 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">53.5 to 54.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">540 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">54.5 to 55.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">550 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">55.5 to 56.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">560 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">56.5 to 57.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">570 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">57.5 to 58.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">580 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">58.5 to 59.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">590 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">59.5 to 60.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">600 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">60.5 to 61.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">610 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">61.5 to 62.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">620 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">62.5 to 63.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">630 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">63.5 to 64.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">640 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">64.5 to 65.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">650 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">65.5 to 66.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">660 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">66.5 to 67.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">670 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">67.5 to 68.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">680 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">68.5 to 69.4 kg</p></td>
<td align="left">
<p style="text-indent:0em;">690 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥69.5 kg</p></td>
<td align="left">
<p style="text-indent:0em;">700 mL</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Concomitant therapy: </i>Prior to delandistrogene moxeparvovec infusion, an oral corticosteroid regimen should be administered to reduce the risk of an immune response and continued for ≥60 days unless early tapering is indicated. Corticosteroid dose for pre- and post- delandistrogene infusion and taper are determined by patient's previous baseline corticosteroid regimen (see tables; dose modification required for abnormal liver function).</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Recommended Oral Corticosteroid Dosing for Pre- and Post-Delandistrogene Infusion</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Baseline corticosteroid dosing</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Corticosteroid regimen<sup>a</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Recommended maximum total daily dose</b>
<b></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Corticosteroid taper</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a</sup> Deflazacort is not recommended for use as the corticosteroid for this purpose.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">Daily or intermittent dosing</p></td>
<td align="left">
<p style="text-indent:0em;">Start <b>1 day prior</b> to infusion: Prednisone 1 mg/kg/day (or equivalent) <b>and</b> continue baseline dose.</p></td>
<td align="left">
<p style="text-indent:0em;">60 mg/day (prednisone equivalent)</p></td>
<td align="left">
<p style="text-indent:0em;">Taper over 2 weeks or longer if clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">High dose for 2 days/week</p></td>
<td align="left">
<p style="text-indent:0em;">Start <b>1 day prior</b> to infusion: Prednisone 1 mg/kg/day (or equivalent) on days without high-dose corticosteroid treatment <b>and</b> continue baseline dose.</p></td>
<td align="left">
<p style="text-indent:0em;">60 mg/day (prednisone equivalent)</p></td>
<td align="left">
<p style="text-indent:0em;">Taper over 2 weeks or longer if clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Not on corticosteroids</p></td>
<td align="left">
<p style="text-indent:0em;">Start <b>1 week prior</b> to infusion: 1.5 mg/kg/day.</p></td>
<td align="left">
<p style="text-indent:0em;">60 mg/day (prednisone equivalent)</p></td>
<td align="left">
<p style="text-indent:0em;">Taper over 4 weeks or longer if clinically indicated</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hepatic impairment following infusion (GGT ≥150 U/L and/or other clinically significant liver function abnormalities [eg, total bilirubin &gt;2 x ULN]):</i></b> Modify corticosteroid dose (see table).</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Oral Corticosteroid Dose Modification for Liver Function Abnormalities Following Delandistrogene Infusion</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Baseline corticosteroid dosing</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Modified corticosteroid dose<sup>a</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Recommended maximum total daily dose</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>Deflazacort is not recommended for use as the corticosteroid for this purpose.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">Daily or intermittent dosing</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to prednisone 2 mg/kg/day (or equivalent) <b>and</b> continue baseline dose.</p></td>
<td align="left">
<p style="text-indent:0em;">120 mg/day (prednisone equivalent)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">High dose for 2 days/week</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to prednisone 2 mg/kg/day (or equivalent) taken on days without high-dose corticosteroid treatment <b>and</b> continue baseline dose.</p></td>
<td align="left">
<p style="text-indent:0em;">120 mg/day (prednisone equivalent)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Not on corticosteroids</p></td>
<td align="left">
<p style="text-indent:0em;">Increase to prednisone 2.5 mg/kg/day (or equivalent).</p></td>
<td align="left">
<p style="text-indent:0em;">120 mg/day (prednisone equivalent)</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F58359768"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F58359769"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Postpone administration in patients with acute liver disease until resolved or controlled. Patients with preexisting hepatic impairment or chronic hepatic viral infection may be at increased risk for hepatotoxicity; assess risk vs benefit. Acute liver injury may occur after therapy and may require adjustment of concomitant corticosteroid dose (see "Dosing: Pediatric"). Monitor liver function closely (clinical exams, GGT, and total bilirubin).</p></div>
<div class="block arsc drugH1Div" id="F58819267"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acute serious liver injury, including <b>increased liver enzymes</b> and <b>increased serum bilirubin</b>, have been observed with delandistrogene moxeparvovec. Most cases resolved spontaneously or with corticosteroids and resolved within 2 months, although one case required hospitalization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37539981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37539981'])">Ref</a></span>). There have been no cases of liver failure reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37497476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37497476'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-left:2em;">
<i>Mechanism:</i> Dose-related; related to pharmacologic action. Associated with adaptive immune response on the liver secondary to viral capsid degradation and presentation by hepatocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37539981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37539981'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-left:2em;">
<i>Onset:</i> Delayed; liver function test elevation has been reported 7 to 8 weeks post infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37539981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37539981'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-left:2em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting liver impairment, chronic hepatic condition, or acute liver disease</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F58339711"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (35%), vomiting (65%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (25%; including increased gamma-glutamyl transferase, increased glutamate dehydrogenase, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum bilirubin)<span class="lexi-table-link-container"> (<a aria-label="Increased Liver Enzymes table link" class="lexi-table-link" data-table-id="lexi-content-increased-liver-enzymes" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-liver-enzymes')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Liver Enzymes</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Liver Enzymes" frame="border" id="lexi-content-increased-liver-enzymes" rules="all">
<caption style="text-align:center;">
<b>Delandistrogene Moxeparvovec: Adverse Reaction: Increased Liver Enzymes</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Delandistrogene Moxeparvovec)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Delandistrogene Moxeparvovec)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">21</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (20%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Myocarditis, troponin increased in blood specimen</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury</p></div>
<div class="block coi drugH1Div" id="F58336330"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Any deletion in exon 8 and/or exon 9 in the Duchenne muscular dystrophy gene.</p></div>
<div class="block war drugH1Div" id="F58364688"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Myositis: Immune-mediated myositis has been observed in patients with deletion mutations involving exon 8 and/or exon 9 in the Duchenne muscular dystrophy gene ~1 month after initial infusion. Consult physician immediately if unexplained muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, occurs; immunomodulatory treatment (eg, immunosuppressants [eg, calcineurin inhibitor]) may be considered if these symptoms occur.</p></div>
<div class="block dosfc drugH1Div" id="F58441731"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Elevidys is provided in a customized kit containing ten to seventy 10 mL single-dose vials, with each kit constituting a dosage unit based on the patient’s body weight.</p></div>
<div class="block foc drugH1Div" id="F58441051"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Kit, Intravenous [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Elevidys: Delandistrogene moxeparvovec-rokl 1.33 × 10<sup>13</sup> vector genomes/mL</p></div>
<div class="block geq drugH1Div" id="F58441049"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58481998"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 10.0-10.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 10.5-11.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">11 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 11.5-12.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 12.5-13.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">13 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 13.5-14.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">14 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 14.5-15.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 15.5-16.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 16.5-17.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 17.5-18.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 18.5-19.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">19 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 19.5-20.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 20.5-21.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">21 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 21.5-22.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 22.5-23.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">23 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 23.5-24.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">24 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 24.5-25.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 25.5-26.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">26 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 26.5-27.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">27 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 27.5-28.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">28 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 28.5-29.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">29 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 29.5-30.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 30.5-31.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">31 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 31.5-32.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">32 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 32.5-33.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">33 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 33.5-34.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">34 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 50.5-51.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">51 x 10 mL (per each): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Elevidys 59.5-60.4 kg Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 x 10 mL (per each): $0.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F58359845"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: For IV infusion only; do not administer as IV push. Administer peripherally through PVC (non-DEHP), polyurethane IV infusion tubing with a 0.2 micron polyether sulfone in-line filter via a syringe pump over at least 1 to 2 hours; infuse at a rate of &lt;10 mL/kg/hour. Flush with NS before and after administration.</p></div>
<div class="block sts drugH1Div" id="F58364707"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Product is shipped and delivered at ≤−60°C (≤−76°F). Upon receipt, store upright at 2°C to 8°C (36°F to 46°F) for ≤14 days. Do not refreeze; do not return to refrigerator once brought to room temperature. Follow local guidelines on handling of biological waste.</p></div>
<div class="block usep drugH1Div" id="F58339550"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of Duchenne muscular dystrophy (DMD) in ambulatory patients with a confirmed mutation in the DMD gene (FDA approved in ages 4 to &lt;6 years).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>FDA approval for this indication is through an accelerated process; continued approval is dependent on verification of clinical benefit in further trials.</p></div>
<div class="block cyt drugH1Div" id="F58362012"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58362009"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F58364686"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Delandistrogene moxeparvovec is not intended for use in persons who are pregnant.</p></div>
<div class="block mopp drugH1Div" id="F58359846"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Baseline:</i> Liver function, platelets, troponin-I, anti-AAVrh74 antibody titers, signs and symptoms of infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Following treatment:</i> Liver function (clinical exam, GGT, and total bilirubin) weekly for 3 months; continue monitoring if clinically indicated until normal clinical exam and GGT and total bilirubin return to near baseline levels. Platelets weekly for 2 weeks or longer if clinically indicated. Troponin-I weekly for 1 month or longer if clinically indicated. Signs and symptoms of infection (eg, coughing, wheezing, sneezing, runny nose, sore throat, fever), myositis (unexplained increased muscle pain, tenderness, or weakness, including difficulty swallowing, difficulty breathing, or difficulty speaking) and myocarditis (eg, chest pain, shortness of breath).</p></div>
<div class="block pha drugH1Div" id="F58364708"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Delandistrogene moxeparvovec is a nonreplicating, recombinant adeno-associated virus serotype rh74 vector-based gene therapy that delivers a normal copy of the gene encoding a micro-dystrophin protein expressed in normal muscle cells.</p></div>
<div class="block phk drugH1Div" id="F58364709"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes into target muscle tissue groups; vector DNA was detected in all major organs, with the highest amount detected in the liver.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Serum: 12 hours; saliva: 60 hours; urine: 40 hours; feces: 55 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine; feces.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58885309"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Elevidys</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Elevidys (delandistrogene moxeparvovec) [prescribing information]. Cambridge, MA: Sarepta Therapeutics Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37497476">
<a name="37497476"></a>Mendell JR, Shieh PB, McDonald CM, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. <i>Front Cell Dev Biol</i>. 2023;11:1167762. doi:10.3389/fcell.2023.1167762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/delandistrogene-moxeparvovec-pediatric-drug-information/abstract-text/37497476/pubmed" id="37497476" target="_blank">37497476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37539981">
<a name="37539981"></a>Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged ≥4 to &lt;8 years) with duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). <i>Ann Neurol</i>. 2023;94(5):955-968. doi:10.1002/ana.26755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/delandistrogene-moxeparvovec-pediatric-drug-information/abstract-text/37539981/pubmed" id="37539981" target="_blank">37539981</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141856 Version 15.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
